Sale!

Immunohistochemistry Thyroid Carcinoma Panel Test Cost

Original price was: 1,170 د.إ.Current price is: 1,050 د.إ.

-10%

Immunohistochemistry (IHC) Thyroid Carcinoma Panel Test is a specialized diagnostic procedure offered by DNA Labs UAE, designed to aid in the accurate identification and classification of thyroid cancer. This test employs a set of specific antibodies to detect and visualize the presence of certain proteins in tissue samples obtained from the thyroid gland. The presence, absence, or quantity of these proteins can help pathologists determine the type of thyroid carcinoma, providing crucial information that guides treatment decisions.

The IHC Thyroid Carcinoma Panel Test is particularly valuable because thyroid cancers can vary widely in their aggressiveness and response to treatment. By identifying the specific characteristics of the cancer cells, this test enables personalized treatment plans that are tailored to the individual’s specific type of thyroid cancer, potentially improving outcomes.

The cost of the Immunohistochemistry Thyroid Carcinoma Panel Test at DNA Labs UAE is 1050 AED. Given the complexity and the specialized nature of this test, it represents a critical investment in the accurate diagnosis and management of thyroid cancer. Patients undergoing this test can expect a detailed analysis of their thyroid tissue, which will aid their healthcare providers in making informed decisions regarding their treatment and management.

Home  Sample collection service available

  • 100% accuaret Test Results
  • Ranked as Most trusted Genetic DNA Lab
  • This test is not intended for medical diagnosis or treatment
Guaranteed Safe Checkout

IMMUNOHISTOCHEMISTRY THYROID CARCINOMA PANEL Test

At DNA Labs UAE, we offer the IMMUNOHISTOCHEMISTRY THYROID CARCINOMA PANEL test, a diagnostic tool used to determine the presence and characteristics of thyroid carcinoma, a type of cancer that affects the thyroid gland.

Test Components

  • CK-19
  • HBME-1
  • BRAF
  • Calcitonin
  • Synaptophysin
  • Thyoglobulin
  • PTF-1

Price

1050.0 AED

Sample Condition

Submit tumor tissue in 10% Formal-saline OR Formalin fixed paraffin embedded block. Ship at room temperature. Provide a copy of the Histopathology report, Site of biopsy, and Clinical history.

Report Delivery

  • Sample: Daily by 6 pm
  • Report Block: 5 days
  • Tissue Biopsy: 5 days
  • Tissue large complex: 7 days

Method

Immunohistochemistry

Test Type

Cancer

Doctor

Oncologist

Test Department

HISTOLOGY

Pre Test Information

Provide a copy of the Histopathology report, Site of biopsy, and Clinical history.

Test Details

The IMMUNOHISTOCHEMISTRY THYROID CARCINOMA PANEL test is a diagnostic tool used to determine the presence and characteristics of thyroid carcinoma, a type of cancer that affects the thyroid gland. This panel test involves the use of immunohistochemistry, a technique that utilizes specific antibodies to detect and visualize specific proteins in tissue samples.

The antibodies used in this panel are specific to markers that are commonly expressed in thyroid carcinoma. The panel typically includes the following markers:

  1. Thyroid transcription factor-1 (TTF-1): TTF-1 is a nuclear protein that is expressed in normal thyroid tissue and is often used as a marker for thyroid carcinoma.
  2. Thyroglobulin: Thyroglobulin is a protein that is produced by normal thyroid cells and is typically elevated in thyroid carcinoma.
  3. Calcitonin: Calcitonin is a hormone that is produced by certain thyroid cells, and elevated levels can be indicative of medullary thyroid carcinoma.
  4. PAX8: PAX8 is a transcription factor that is expressed in thyroid follicular cells and is often used as a marker for thyroid carcinoma.

By analyzing the expression of these markers in tissue samples, pathologists can determine the presence and type of thyroid carcinoma. This information is crucial for guiding treatment decisions and predicting patient outcomes.

Contact DNA Labs UAE today to schedule the IMMUNOHISTOCHEMISTRY THYROID CARCINOMA PANEL test and consult with our expert oncologists.

Test Name IMMUNOHISTOCHEMISTRY THYROID CARCINOMA PANEL Test
Components *CK-19*HBME-1*BRAF*Calcitonin*Synaptophysin*Thyoglobulin*PTF-1
Price 1050.0 AED
Sample Condition Submit tumor tissue in 10% Formal-saline OR Formalin fixed paraffin embedded block. Ship at room temperature. Provide a copy of the Histopathology report, Site of biopsy and Clinical history.
Report Delivery Sample Daily by 6 pm; Report Block: 5 days Tissue Biopsy: 5 days Tissue large complex : 7 days
Method Immunohistochemistry
Test type Cancer
Doctor Oncologist
Test Department: HISTOLOGY
Pre Test Information Provide a copy of the Histopathology report, Site of biopsy and Clinical history.
Test Details

The IMMUNOHISTOCHEMISTRY THYROID CARCINOMA PANEL test is a diagnostic tool used to determine the presence and characteristics of thyroid carcinoma, a type of cancer that affects the thyroid gland.

This panel test involves the use of immunohistochemistry, a technique that utilizes specific antibodies to detect and visualize specific proteins in tissue samples. The antibodies used in this panel are specific to markers that are commonly expressed in thyroid carcinoma.

The panel typically includes the following markers:

1. Thyroid transcription factor-1 (TTF-1): TTF-1 is a nuclear protein that is expressed in normal thyroid tissue and is often used as a marker for thyroid carcinoma.

2. Thyroglobulin: Thyroglobulin is a protein that is produced by normal thyroid cells and is typically elevated in thyroid carcinoma.

3. Calcitonin: Calcitonin is a hormone that is produced by certain thyroid cells, and elevated levels can be indicative of medullary thyroid carcinoma.

4. PAX8: PAX8 is a transcription factor that is expressed in thyroid follicular cells and is often used as a marker for thyroid carcinoma.

By analyzing the expression of these markers in tissue samples, pathologists can determine the presence and type of thyroid carcinoma. This information is crucial for guiding treatment decisions and predicting patient outcomes.